CXCR2 has been found to be involved in multiple aspects of cancer progression. It contributes to tumor growth, angiogenesis, metastasis, and the modulation of the immune microenvironment. The aberrant expression or activation of this receptor is often associated with poor prognosis in various types of cancers, such as breast cancer, colorectal cancer, and melanoma.
